*To the Editor*,

*Helicobacter pylori* is the most highlighted and prominent pathogenic bacterium of the human gastric submucosa; it colonizes the stomachs of half of the world\'s population \[[@bib1]\]. Most of the populations living in developing countries are predominantly infected during childhood and the amount of infection in these areas is nearly 100% \[[@bib2]\]. With the introduction of *H. pylori* as a first-class factor for gastric cancer (GC) by the International Agency for Research on Cancer in 1994, extensive attention was paid by gastroenterologists to this bacterium. *Helicobacter pylori* has been identified as the aetiological cause of chronic gastritis, peptic ulcer diseases (PUD), gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma and some extra-gastrointestinal disorders \[[@bib3], [@bib4], [@bib5]\]. A significant number of *H. pylori*-infected individuals remain asymptomatic and PUD is observed in only 15%--20% and GC in 1%--2% of individuals, so the question arises as to why the clinical symptoms are observed in only a small part of the population with the rest remaining as asymptomatic carriers. Based on available evidence, genetic characteristics and *H. pylori* strain virulence factors, host genome and its epigenetic events, and the environmental conditions can play decisive roles in the incidence of *H. pylori*-related gastrointestinal outcomes \[[@bib1],[@bib5], [@bib6], [@bib7]\].

The most famous *H. pylori* virulence factors include *vacA* and *cagA*. The *cagA* (cytotoxin-associated gene A) encodes a toxin of 120--140 kDa, which is phosphorylated at the site of its own EPIYA motif (tyrosine residue) by Src kinase family proteins of the host and, subsequent to phosphorylation, *cagA*-P induces the 'hummingbird phenotype' and incidence of GC through alteration in cytoskeletal rearrangements, cell survival and proliferation, and changes in polarity \[[@bib8]\]. According to the previous studies, nearly 100% of *H. pylori* isolates in the Japanese population produce and express *cagA* \[[@bib9]\]. Iran is the fourth country in terms of GC prevalence in Asia, and nearly 69% of *H. pylori* isolates in Iranian patients harbour (containing, transporting) *cagA* \[[@bib10]\]. The *vacA* (vacuolating cytotoxin gene A) is another virulence factor, which releases cytochrome c from the mitochondria by entering into the gastric epithelium, induces apoptosis, destroys tight junctions and intercellular connections, and produces vacuole in the host cells \[[@bib11]\]. The *vacA* consists of five polymorphic regions including signal sequence (s1/s2), middle (m1/m2), intermediate (i1/i2), deletion (d1/d2) and c (c1/c2). Only about 50% of the *H. pylori* strains encode the *vacA* \[[@bib12],[@bib13]\]. Also, the combination of each region determines the vacuolating formation strength. For example, the vacA s1m1 strains express a large amount of toxin with high vacuolating formation strength, whereas s1m2 strains produce a moderate amount of toxin and s2m2 strains are not, or are rarely, toxic \[[@bib14]\]. There are controversial results regarding the relationship between i1/i2 segments \[[@bib15],[@bib16]\]. In this study, for the first time in Iran, we conducted a meta-analysis study to assess the possible role and relationship of *vacA* i1/i2 in the Iranian population.

Potentially supported documents were collected by searching the PubMed, Scopus, Embase, Elton B. Stephens Company (EBSCO), Google scholar, Scientific Information Database (SID), Islamic Science Citation Database (ISC), and magiran databases. The documents were investigated using the keywords '*Helicobacter pylori*', 'Peptic Ulcer Disease', 'Gastric Cancer', '*VacA* protein' and 'Iran'. Studies were collected up to April 2020, without language and time constraints, and all the original articles (including case--control, cohort, prospective, retrospective), letters to the editor and congress abstracts that were about determining the frequency of *vacA* i1/i2 genotypes in the Iranian PUD and GC patients were studied; information including the first author, publication year, location, distribution of gender and age, number of *H. pylori* strains and distribution of *vacA* i1/i2 genotypes are listed in [Table 1](#tbl1){ref-type="table"}.Table 1Characteristics of included studyTable 1Ref.Publication yearLocationFemale/male; age*H. pylori* strains*vacA* i1/2 genotypeTotalPUGCi1i2i1i2i1i2Bakhti et al. \[[@bib17]\]2019ArdabilNA; 46.5229011212034233217Mottaghi et al. \[[@bib18]\]2014Tabriz45/44; NA894643611213Bakhti et al. \[[@bib19]\]2015Ardabil77/100; 5017776983423NANABakhti et al. \[SID\]2014ArdabilNA; NA1607790NANA37NABakhti et al. \[SID\]2014ArdabilNA; NA171333333NANANAAbdi et al. \[[@bib20]\]2017Ardabil44/85; 53.571034027NANA249Bakhti et al. \[[@bib21]\]2015TehranNA; 45.342171021063423299Douraghi et al. \[[@bib21]\]2009Tehran91/116; 44.8 ± 162071599420NA30NA[^1]

The relationship of the infection with *vacA* i1/2 strains and development of GC lesions was calculated using the odds ratio index with 95% CI. The random effects model (Dersimonian and Laird method) was used in cases of high heterogeneity including *I*^2^ index \>25% and Cochran\'s *Q*-test p \< 0.005; the statistical analysis was performed using Comprehensive Meta-Analysis (CMA v. 2.0) software. The publication bias was also measured according to Egger\'s regression method \[[@bib4]\].

The eight studies that met our criteria were entered into the present analysis \[[@bib12],[@bib17], [@bib18], [@bib19], [@bib20], [@bib21]\]. The studies were conducted in the period 2009--2019, five studies were performed in Ardabil, two in Tehran and one in Tabriz. In this study, the data from 1746 patients with an average age of about 48 ± 4 years were evaluated; about 41.9% of the patients were women and the rest were men. In general, 1414 strains of *H. pylori* were isolated from the patients in the present study. The frequency of *vacA* i1 in the present study was about 45.61% and the frequency of *vacA* i2 was about 43.21%. Based on the results of statistical analysis, we did not observe any significant relationship between infection acquisition with *H. pylori vacA* i1 or i2 and development of PUD or GC in the Iranian patients ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Forrest plots of the *vacA* i1/i2 association with *Helicobacter pylori*-related gastrointestinal diseases. (a) *vacA* i1 in peptic ulcer disease (PUD) and gastric cancer (GC) development; (b) *vacA* i2 in PUD and GC development; (c) *vacA* i1 in PUD development; (d) *vacA* i2 in PUD development; (e) *vacA* i1 in GC development; (f) *vacA* i2 in GC development.Fig. 1

In the next step, we evaluated the role of infection with the *H. pylori* strains *cagA* + *vacA* i1/2 with PUD and GC, although no significant relationship was obtained for this. Moreover, because of insufficient information and the ambiguity of some results, we could not determine the role of *cagA*+/i1 or i2/s1m1 strains or *vacA* i1 or i2/s1m1 strains in the formation and development of PUD and GC. According to Egger\'s regression intercept (bias studies) no publication bias was observed in the included studies. It seems that *vacA* i1 or i2 has no role in the formation and onset of PUD and GC in the Iranian population.

The i locus is located between regions s and m and plays a functional role in the activity and formation of vacuole, such that the strains containing *vacA* i1 have the ability of vacuolating formation, while *vacA* i2 strains are unable to produce vacuolation \[[@bib22]\]. Our data on the role of constellation in *vacA* polymorphic regions and the synergistic effects between *vacA* i1/2 alleles and *cagA* in the occurrence of PUD and GC are limited ([Fig. 2](#fig2){ref-type="fig"}).Fig. 2The schematic of the vacA role in *Helicobacter pylori* pathogenesis.Fig. 2

In this study, we showed that infection with *vacA* i1/2 strains had no effect on the development and severity of PUD and GC in the Iranian population. We also demonstrated that the combination of *vacA* i1/2 and *cagA* played no roles in the formation of *H. pylori*-related gastrointestinal issues.

In a study of strains isolated from Iraqi and Iranian patients with gastric ulcer, the *vacA* i1 genotype was only associated with gastric ulcer in the Iraqi patients \[[@bib23]\]. However, studies in East Asia have found a significant relationship between the *vacA* i1 allele as well as PUD and GC, such that i1 is considered a biomarker for the *H*. *pylori*-related gastrointestinal disease. Bagheri et al. revealed the high abundance of *vacA* i1 allele in Iranian patients \[[@bib24], [@bib25], [@bib26]\].

In their study on the Swedish population, Karlsson et al. found no significant relationship between *vacA* i1 and PUD or GC development \[[@bib27]\]. González-Rivera et al. found that by inhibiting the nuclear factor of activated T cells, i1 suppresses interleukin-2 production and prevents the formation of chronic inflammation and PUD \[[@bib28]\]. However, Memon et al. observed a significant relationship between i1 genotype and duodenal ulcer \[[@bib29]\].

In their meta-analysis, Liu et al. stated that infection with the *vacA* i1 genotype was significantly related to gastric cancer. They stated that the *vacA* i1 genotype had a significant relationship with GC, particularly in Asian countries (OR 10.89; 95% CI 4.11--20.88) \[[@bib30]\]. Sugimoto et al. also showed that there is a significant relationship between *vacA* i1 genotype and GC development in Asian countries \[[@bib14]\]. However, they noted in their study that a great number of s1, m1 and s1m1 strains contained i1. Hence, it is not yet possible to make a definite decision as to whether the *vacA* i1 genotype causes GC \[[@bib14]\]. Numerous studies have also shown that the frequency of the *vacA* i1 genotype is high in *vacA* s1m1 strains (based on the results of many studies, these strains increase the risk of PUD and GC), which could alter the results and lead to false negatives \[[@bib22],[@bib23],[@bib31],[@bib32]\]. In their meta-analysis, Pourmohammadi et al. showed that the *vacA* i1 genotype has no role in the GC development. They stated that *cagA* and *vacA* s1m1 have a significant relationship with the GC development \[[@bib33]\].

Hence, the role of host genetics and environmental factors in the occurrence of PUD and GC, as well as the high frequency of *cagA*+ and *vacA* s1m1 strains in individuals with PUD and GC, cannot be definitely decided through the impact of *vacA* i1/2 alleles in PUD and GC development because of the diversity of the strains and differences in the frequency of *vacA* i1/2 in strains of different regions of the world. We need to plan and implement more and larger studies.
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